Skip to main content

Table 2 Disease characteristics by age group

From: Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life

 

Age < 70 years (N = 333) n (%)

Age ≥ 70 years (N = 188) n (%)

All patients (N = 521) n (%)

Histology

   

   Non-squamous cell carcinoma

283 (85.0)

161 (85.6)

444 (85.2)

   Squamous cell carcinomaa

50 (15.0)

27 (14.4)

77 (14.8)

Disease stage at study entry

   

   Stage IIIa

18 ( 5.4)

17 ( 9.0)

35 ( 6.7)

   Stage IIIb

65 (19.5)

38 (20.2)

103 (19.8)

   Stage IV

250 (74.1)

133 (70.7)

383 (73.5)

Karnofsky Index (KI)

   

   KI ≥ 80%

207 (62.2)

116 (61.7)

323 (62.0)

   KI 70%

89 (26.7)

45 (23.9)

134 (25.7)

   KI 60%

27 ( 8.1)

18 ( 9.6)

45 ( 8.6)

   KI 50%

10 ( 3.0)

8 ( 4.3)

18 ( 3.5)

   Missing data

0 ( 0.0)

1 ( 0.5)

1 ( 0.2)

  1. N = total number of patients, n = number of patients
  2. a) The study started in 2007, before the label change in April 2008 which restricted the use of pemetrexed to patients with non-squamous cell carcinoma
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us